DNB Asset Management AS Has $22.28 Million Position in Becton, Dickinson and Company $BDX

Key Points

• DNB Asset Management AS more than doubled its stake in Becton, Dickinson and Company in the fourth quarter, raising holdings by 107.3% to 114,809 shares worth about $22.28 million.
• Becton, Dickinson reported better-than-expected quarterly results, with EPS of $2.90 versus $2.77 expected and revenue of $4.71 billion, up 5.2% year over year.
• The company also announced a quarterly dividend of $1.05 per share and maintained a buyback authorization, while analysts currently rate the stock a consensus “Hold” with an average target price of $184.86.

DNB Asset Management AS boosted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 107.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 114,809 shares of the medical instruments supplier's stock after purchasing an additional 59,414 shares during the quarter. DNB Asset Management AS's holdings in Becton, Dickinson and Company were worth $22,281,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock valued at $7,118,282,000 after acquiring an additional 4,223,149 shares in the last quarter. State Street Corp raised its stake in shares of Becton, Dickinson and Company by 3.4% during the 3rd quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier's stock worth $2,596,496,000 after purchasing an additional 459,219 shares during the period. First Eagle Investment Management LLC raised its stake in shares of Becton, Dickinson and Company by 16.5% during the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier's stock worth $2,260,139,000 after purchasing an additional 1,651,592 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Becton, Dickinson and Company by 3.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier's stock worth $1,841,083,000 after purchasing an additional 336,110 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of Becton, Dickinson and Company by 9,056.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock worth $979,290,000 after purchasing an additional 5,174,944 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $143.32 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The stock has a 50 day moving average price of $154.80 and a two-hundred day moving average price of $179.33. The company has a market capitalization of $39.49 billion, a P/E ratio of 36.28, a PEG ratio of 10.16 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter in the previous year, the company posted $3.35 earnings per share. The business's revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.9%. Becton, Dickinson and Company's payout ratio is presently 106.33%.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase plan on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's leadership believes its shares are undervalued.

Analysts Set New Price Targets

BDX has been the topic of a number of research reports. Evercore boosted their price objective on Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Zacks Research raised Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a report on Friday, April 10th. Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an "equal weight" rating in a report on Friday, May 8th. The Goldman Sachs Group started coverage on Becton, Dickinson and Company in a report on Friday, April 10th. They set a "neutral" rating and a $167.00 target price for the company. Finally, TD Cowen reduced their target price on Becton, Dickinson and Company from $189.00 to $163.00 and set a "hold" rating for the company in a report on Monday, May 4th. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and a consensus target price of $184.86.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the business's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 1,102 shares of company stock valued at $198,909 in the last ninety days. Insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.